Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease
Abstract
BACKGROUND: It has been shown that adoptive immunotherapy with Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes (CTL) is effective for the treatment of EBV‐induced lymphoproliferative disease in stem cell transplantation recipients and organ transplantation recipients. The role of EBV CTL in other tumors for which this virus has been implicated in pathogenesis, such as EBV‐positive Hodgkin disease (HD), has not been demonstrated clearly.METHODS: To investigate the antitumor effects and toxicity of allogeneic EBV CTL in EBV‐positive HD, the authors initiated a pilot trial in which EBV CTL were cultured from allogeneic, partially human leukocyte antigen‐matched donors and were infused into patients who had therapy‐refractory disease. The first cohort of 3 patients (Cohort I) received 3 separate infusions of EBV CTL (5.0 × 106 EBV CTL/kg per dose), and the second cohort (Cohort II) received 30 mg/m2 per day of fludarabine for 3 days followed by a single CTL infusion (1.5 × 107 EBV CTL/kg).RESULTS: All three patients in Cohort I had decreases in measurable disease after EBV CTL infusions, and one of those patients was without evidence of disease 22 months after infusion. Two of 3 patients in Cohort II had decreases in measurable disease, although it was not determined whether those decreases were related to fludarabine or to CTL, and 1 patient in Cohort II had 7 months without disease progression. Unlike the patients in Cohort I, fludarabine recipients did not have increases in antidonor CTL responses. Donor cells could not be detected in any of the CTL recipients.CONCLUSIONS: Adoptive immunotherapy with allogeneic EBV CTL was safe for patients with recurrent, refractory, EBV‐positive HD; and clinical responses may be observed without the establishment of detectable donor lymphoid chimerism. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 33 references indexed in Scilit:
- Safety of allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T lymphocytes for patients with refractory EBV‐related lymphomaBritish Journal of Haematology, 2002
- The role of cytokines in classical Hodgkin lymphomaBlood, 2002
- Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphomaInternational Journal of Cancer, 2001
- Expression of the Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) 1 and 2 is a Characteristic Feature of Hodgkin and Reed-Sternberg CellsLaboratory Investigation, 2000
- Regulatory T CellsCell, 2000
- High Expression of the CC Chemokine TARC in Reed-Sternberg CellsThe American Journal of Pathology, 1999
- Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.Journal of Experimental Medicine, 1992
- Detection of Epstein‐Barr Virus DNA in Reed‐Sternberg Cells of Hodgkin's Disease Using the Polymerase Chain Reaction and in situ HybridizationJapanese Journal of Cancer Research, 1990
- Hodgkin's Disease and Epstein-Barr VirusNew England Journal of Medicine, 1989
- Hodgkin's Disease in Patients with Previous Infectious Mononucleosis: 30 Years' ExperienceBMJ, 1974